Informations

The “Northern Breast Cancer Salon Annual Progress Review” was held from January 3–5, 2025, in Beijing. The conference comprehensively reviewed the latest advances in breast cancer diagnosis, treatment, and research over the past year, delving into the latest findings for various breast cancer subtypes and their impact on clinical practice. The conference also focused on…

Oncology Frontier: Could you briefly introduce the key advancements in the treatment of advanced triple-negative breast cancer (TNBC) in 2024? How have these advancements impacted patients’ survival or quality of…

With the ongoing advancements in breast cancer research, BRCA gene mutations, as a significant genetic risk factor for breast cancer, have attracted increasing attention. In this article, Dr. Songqing Ye from Fujian Provincial Hospital will provide a detailed discussion on the prognosis and treatment advances for BRCA-mutated breast cancer patients, covering the association between BRCA…

During the launch event, Oncology Frontier interviewed several renowned experts, including Professor Guangyu Liu from Fudan University Shanghai Cancer Center, Professor Li Ma from The Fourth Hospital of Hebei Medical…

1. Oncology Frontier: As the Chairperson of this forum, could you share the topics that you found most compelling during the event? Dr. Yongchang Zhou: Absolutely. This year’s forum was…

Meeting at the Summit，China’s Original Research Takes the International Stage Oncology Frontier: Could you review China’s original research achievements in breast cancer in 2024? Dr. Zefei Jiang: 2024 has been…

The global multicenter, randomized, double-blind phase III RATIONALE-305 trial, led by Professor Ruihua Xu as the Global Leading PI, demonstrated that tislelizumab combined with chemotherapy significantly improves overall survival (OS) compared to placebo plus chemotherapy in patients with advanced gastric cancer. This study offers a new first-line treatment option for patients with advanced gastric cancer.…

Pancreatic cancer, often called the “king of cancers,” remains a formidable disease with poor patient outcomes. Challenges stem from the complexity and invasiveness of surgical procedures and limited progress in systemic therapies, which are still largely chemotherapy-based. However, 2024 brought new developments in pancreatic minimally invasive surgery and innovative treatment strategies. In an interview with…